To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
The bill’s titles are written by its sponsor.
May 16, 2017
Passed House & Senate (President next) on Aug 3, 2017
This bill was passed by Congress on August 3, 2017 and goes to the President next.
Representative for Oregon's 2nd congressional district
Read Text »
Last Updated: Aug 5, 2017
Length: 86 pages
H.R. 2430 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2017). H.R. 2430 — 115th Congress: FDA Reauthorization Act of 2017. Retrieved from https://www.govtrack.us/congress/bills/115/hr2430
“H.R. 2430 — 115th Congress: FDA Reauthorization Act of 2017.” www.GovTrack.us. 2017. August 18, 2017 <https://www.govtrack.us/congress/bills/115/hr2430>
|title=H.R. 2430 (115th)
|accessdate=August 18, 2017
|author=115th Congress (2017)
|date=May 16, 2017
|quote=FDA Reauthorization Act of 2017
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.